arrow
G

Giovanni Randon

fondazione irccs istituto nazionale tumori
H指数:28
被引数:2,653

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Consistency of Radiological Staging in Resectable Mismatch-Repair Proficient Colon Cancer: An Interobserver Agreement Study

可切除性错配修复 proficient 结直肠癌的放射学分期一致性:一项观察者间一致性研究

2026-06-010
PRE
Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years

极早期转移性结直肠癌的分子和临床侵袭性差异:30-39岁与40-49岁患者间的生存和基因组分歧

2026-06-010
OAAI
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer

黏液性组织学与微卫星不稳定性高转移性结直肠癌患者对免疫检查点阻断的抵抗

2026-05-010
OA
Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer

微卫星稳定型转移性结直肠癌对化疗免疫联合治疗的反应的空间预测因子

2026-04-250
OAAI
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer

早期局部晚期直肠癌患者的临床特征和预后

2026-02-230
PRE
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: a secondary endpoint of the ARMANI phase 3 trial

帕克他赛和雷莫芦单抗序贯维持治疗在晚期胃肠癌中的患者报告结局:ARMANI III期试验的次要终点

2025-10-200
PRE
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials

原发肿瘤侧别及负超选择对RAS野生型转移性结直肠癌患者抗EGFR为基础维持疗法的影响:两项随机临床试验的个体患者数据合并分析

2025-08-280
OAAI
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma

II期PANDORA试验的设计与原理:晚期默克尔细胞癌的一线化疗免疫疗法

2025-06-120
OA
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO

曲美木单抗和度伐利尤单抗作为微卫星不稳定性高、可切除的胃或胃食管结合部腺癌患者的新辅助治疗或非手术治疗策略:GONO开展的INFINITY研究

2025-03-018
PRE
The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors
2025-01-010
PRE
Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation study

非侵入性CT影像组学生物标志物预测结直肠癌微卫星稳定性: 一项多中心验证研究

2024-08-261
OAAI
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
2024-07-014
OA
Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials

性别对局部晚期微卫星不稳定性高的胃或胃食管交界癌的预后和预测影响: 一项随机临床试验的个体患者数据汇总分析

2024-05-010
PRE
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin
2023-12-013
PRE
Artificial intelligence-based pathomics biomarker predict primary resistance to first-line treatment in metastatic colorectal cancers

基于人工智能的病理组学生物标志物预测转移性结直肠癌一线治疗的原发性耐药

2023-10-010
PRE
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial

评估卡博替尼联合兰瑞肽在胃肠胰腺和胸部神经内分泌肿瘤中的安全性和活性: II期LOLA试验的原理和方案

2023-09-266
OAAI
Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy
2023-09-253
OA